Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

This trial tests a combination of three drugs — lurbinectedin, weekly paclitaxel (a chemotherapy), and bevacizumab (a targeted drug that blocks tumor blood supply) — in women with ovarian cancer that stopped responding to platinum-based chemotherapy. **You may be eligible if...** - You are 18 years or older - You have ovarian cancer that is resistant to platinum chemotherapy (meaning prior platinum treatment did not work or stopped working) - You are able to tolerate and comply with the treatment schedule **You may NOT be eligible if...** - Your ovarian cancer still responds to platinum-based chemotherapy - You cannot comply with the study visits and procedures - You have certain other health conditions that make the combination unsafe Talk to your doctor to see if this trial is right for you.